Foghorn Therapeutics, a Cambridge, MA-based drug discovery company, raised $50M in funding.
Flagship Pioneering developed and launched Foghorn through its innovation foundry, Flagship VentureLabs, and has made the initial capital commitment.
Founded by Cigall Kadoch, Ph.D., of the Dana-Farber Cancer Institute, Harvard Medical School, and the Broad Institute, Douglas Cole, M.D., of Flagship Pioneering, and Gerald Crabtree, M.D., of the Howard Hughes Medical Institute and Stanford University, and led by CEO Adrian Gottschalk, formerly senior vice president and neurodegeneration therapeutic area head at Biogen, Foghorn uses a proprietary Gene Traffic Control™ product platform to discover and develop develops treatments for cancer and other serious diseases by based on novel insights into the chromatin regulatory system
Since establishing operations in 2016, the company has developed a product platform that has generated new insights into disease, created six programs, and built a discovery engine that is yielding many additional targets.
Foghorn is in the process of developing drug candidates across a range of cancers and is exploring applications of Gene Traffic Control in neurology and immunology.